[HTML][HTML] Miliary tuberculosis in a Crohn's disease patient: the risk beyond the screening
LP Carvalho, MA Túlio, JP Rodrigues… - GE-Portuguese Journal …, 2018 - karger.com
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
[HTML][HTML] Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening
LP Carvalho, MA Túlio, JP Rodrigues… - … Portuguese Journal of …, 2018 - ncbi.nlm.nih.gov
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening
LP Carvalho, MA Túlio, JP Rodrigues, C Chagas - sidalc.net
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening.
LP Carvalho, MA Túlio, JP Rodrigues… - GE Portuguese Journal …, 2018 - europepmc.org
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening
LP Carvalho - Portuguese Journal of Gastroenterology, 2018 - search.proquest.com
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening
LP Carvalho, MA Túlio… - GE Portuguese …, 2018 - pubmed.ncbi.nlm.nih.gov
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening
LP Carvalho, MA Túlio, JP Rodrigues… - GE-Portuguese Journal …, 2018 - karger.com
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening/Tuberculose Miliar na doenca de Crohn--o risco para alem do rastreio
LP Carvalho, MA Tulio, JP Rodrigues… - GE-Portuguese Journal …, 2019 - go.gale.com
Tumor necrosis factor alpha (TNF [alpha]) antagonist is recognized as an effective treatment
to achieve clinical remission and healing mucosal in patients with moderate to severe active …
to achieve clinical remission and healing mucosal in patients with moderate to severe active …
Miliary Tuberculosis in a Crohn's Disease Patient: The Risk beyond the Screening.
LP Carvalho, MA Túlio, JP Rodrigues… - GE Portuguese …, 2019 - search.ebscohost.com
Tumor necrosis factor alpha (TNFα) antagonist is recognized as an effective treatment to
achieve clinical remission and healing mucosal in patients with moderate to severe active …
achieve clinical remission and healing mucosal in patients with moderate to severe active …